NCT07186010 Immunogenomic Dynamics and Biomarkers in Patients With Hepatocellular Carcinoma Receiving Immunotherapy
| NCT ID | NCT07186010 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Asan Medical Center |
| Condition | Hepatocellular Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2020-09-28 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2020-09-28 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
1. Research purpose To perform genomic and immune profiling analysis on blood and tissue samples obtained from blood sampling and tumor biopsy in patients with advanced hepatocellular carcinoma with immuno-oncology treatment. 2. Research Subject Patients who will receive immuno-oncology treatment in recurrent, metastatic, and advanced liver cancer, who meet the selection criteria of the study, do not have exclusion criteria, and voluntarily agree to participate in the study. 3. Number of study subjects 50 people 4. Research Method 1) In patients with advanced hepatocellular carcinoma, peripheral blood will be collected at baseline before treatment, 6 weeks, 12 weeks, 24 weeks, 48 weeks after treatment, and at the time of cancer progression. 2\) Fresh tumors will be stored in the tissue obtained during the biopsy to perform genetic analysis
Eligibility Criteria
Inclusion Criteria: 1. Patients with histologically confirmed HCC, 2. Patients with histologically confirmed locally advanced, recurrent or metastatic HCC, which was judged not to be eligible for surgical resection, liver transplantation or radiofrequency ablation 3. Patients who will receive immuno-oncology treatment Exclusion Criteria: 1. Patients with histologically confirmed fibrolamellar type HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC 2. Patients with concurrent other malignancy 3. Patients who are candidates for local curative treatments such as hepatic resection, liver transplantation, or radiofrequency ablation 4. Patients who have a possibility of confusion in the results of the clinical research
Contact & Investigator
Ju Hyun Shim
PRINCIPAL INVESTIGATOR
Asan Medical Center
Frequently Asked Questions
Who can join the NCT07186010 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07186010 currently recruiting?
Yes, NCT07186010 is actively recruiting participants. Contact the research team at s5854@amc.seoul.kr for enrollment information.
Where is the NCT07186010 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07186010 clinical trial?
NCT07186010 is sponsored by Asan Medical Center. The principal investigator is Ju Hyun Shim at Asan Medical Center. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.